Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and new drug development, writes Mike Banville, CEO and President at ALZpath.

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Mike Fuller & Kim Kennedy Biotechnology companies are in an exceptionally competitive field, with multiple companies competing against each other for a chance to market similar innovative therapeutics ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

With six consecutive years of profitability (ahem, soon to be seven) and a market cap of nearly $13 billion, Genmab A/S represents one of Europe’s brightest biotech triumphs. But such wasn’t always ...